ライフサイエンスコーパス: dose-dense

1 the hospitalization rates ranged from 6.2% (dose-dense AC + P) to 10.0% (TAC), and those who receive

2 than age 65 years, all regimens (aside from dose-dense AC + P) were associated with a higher risk of

3 ide (C), doxorubicin (A) and C, TAC, AC + T, dose-dense AC + paclitaxel (P) or AC + weekly P.

4 r toxicity and dose-delivery were similar to dose-dense AC --> paclitaxel in Cancer and Leukemia Grou

5 Dose-dense AC followed by P/T followed by T is feasible

6 We conducted a pilot study of dose-dense AC followed by PT plus lapatinib (PTL) follow

7 Dose-dense AC followed by PTL and then followed by TL wa

8 Tipifarnib may be safely combined with dose-dense AC using a dose and schedule that significant

9 Dose-dense AC with or without concurrent bevacizumab is

10 e pCR rate after four cycles of preoperative dose-dense AC.

11 end point has already been reported.Although dose-dense adjuvant chemotherapy administered once every

12 Objective: To determine whether tailored dose-dense adjuvant chemotherapy improves the outcomes o

13 prove outcomes is unknown, as is the role of dose-dense adjuvant chemotherapy.

14 cycles of leukocyte nadir-based tailored and dose-dense adjuvant epirubicin and cyclophosphamide ever

15 Salvage chemotherapy regimens integrating dose dense and vertical dose intensification strategies

16 were enrolled; 42 were randomly assigned to dose-dense and 43 to metronomic temozolomide.

17 d by HDC with AHPCS or to receive sequential dose-dense and dose-escalated chemotherapy with doxorubi

18 e feasibility and efficacy of giving uniform dose-dense and dose-intense cytoreductive chemotherapy a

19 s the use up-front of all active agents in a dose-dense and dose-intense fashion, as practiced in Tot

20 a comprehensive 2-step protocol encompassing dose-dense and dose-intense second-line chemotherapy, fo

21 Both dose-dense and metronomic temozolomide regimens were wel

22 erging evidence that other therapies such as dose-dense and metronomic temozolomide regimens, targete

23 To evaluate the efficacy of a dose-dense approach consolidated by up-front high-dose c

24 Randomized trials testing the dose-dense approach have been completed but not yet repo

25 -cell transplant was used in 8% in the Unfav-dose-dense arm and 17% in the Unfav-BEP arm (P = .035).

26 survival (PFS) rates were 58.9% in the Unfav-dose-dense arm and 46.7% in the Unfav-BEP arm (hazard ra

27 progression-free survival (6.6 months in the dose-dense arm and 5.0 months in the metronomic arm).

28 The 1-year survival rate was 80% for the dose-dense arm and 69% for the metronomic arm; median OS

29 There was greater deterioration in the dose-dense arm from baseline to cycle 4 in the Global He

30 rably, with only three patients in the Unfav-dose-dense arm reporting grade 3 motor neurotoxicity at

31 bserved in patients randomly assigned to the dose-dense arm.

32 and Drug Administration and the benefits of dose-dense breast cancer chemotherapy, especially for ho

33 y is to establish the safety and activity of dose-dense brentuximab vedotin combined with ifosfamide,

34 a single-arm, open-label, phase 1/2 study of dose-dense BV-ICE at the Seattle Cancer Care Alliance, U

35 Our data suggest that dose-dense BV-ICE is a rapidly administered and active s

36 g N0-1 RS12-25 without ET response) received dose-dense chemotherapy (CT) followed by ET in the CT tr

37 c, but also predicted improved outcomes from dose-dense chemotherapy (interaction P = .0998 for DFS;

38 likely a result of the reported benefits of dose-dense chemotherapy and the ease of pegfilgrastim ad

39 Weekly dose-dense chemotherapy can be delivered successfully as

40 isk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant

41 rian cancer, we found that first-line weekly dose-dense chemotherapy did not improve overall or progr

42 the sustained long-term benefit of adjuvant dose-dense chemotherapy for node-positive breast cancer.

43 Dose-dense chemotherapy improved DFS in the overall stud

44 addition of recommendations against routine dose-dense chemotherapy in lymphoma and in favor of high

45 r women with HR-positive tumors treated with dose-dense chemotherapy is estimated to be $38.8 million

46 Dose-dense chemotherapy is predicted to be a superior tr

47 were randomly assigned 1:1 to two different dose-dense chemotherapy regimens and 2:1 to ibandronate

48 ing a subset of trials comparing intensified/dose-dense chemotherapy versus standard-dose regimens (D

49 ts with ER+ breast cancer who benefited from dose-dense chemotherapy, and specifically, this benefit

50 rly HR-positive patients do not benefit from dose-dense chemotherapy, limiting pegfilgrastim use woul

51 nscriptional activity predicted benefit from dose-dense chemotherapy, whereas tumor burden and prolif

52 dentify patients most likely to benefit from dose-dense chemotherapy.

53 High treatment efficacy is achieved using dose-dense chemotherapy.

54 h high-risk early breast cancer who received dose-dense chemotherapy.

55 e estimated for patients who were undergoing dose-dense chemotherapy.

56 length less than 21 days as having received dose-dense chemotherapy.

57 after 2002 and estimated US expenditures for dose-dense chemotherapy.

58 l doses) and 55 received a dose-intensified, dose-dense concomitant regimen of epirubicin + cyclophos

59 sequential cyclophosphamide administration, dose-dense consolidation, late intensification, CNS prop

60 Dose-dense (dd) AC followed by paclitaxel (P) is superio

61 Dose-dense (dd) doxorubicin and cyclophosphamide (AC) fo

62 Dose-dense (DD) regimens of combination chemotherapy may

63 Dose-dense (DD) temozolomide results in prolonged deplet

64 ery 2 weeks followed by 4 cycles of tailored dose-dense docetaxel every 2 weeks, or to standard-inter

65 rogenitor cell support (AHPCS) with a modern dose-dense dose-escalated (nonstandard) regimen includin

66 vidence that transplantation was superior to dose-dense dose-escalated therapy.

67 axel + trastuzumab + pertuzumab (THP) versus dose-dense doxorubicin + cyclophosphamide (ddAC) followe

68 Dose-dense doxorubicin and cyclophosphamide (AC) followe

69 asibility trial testing this hypothesis with dose-dense doxorubicin and cyclophosphamide (ddAC).

70 ntial CT consisting of either four cycles of dose-dense doxorubicin at 60 mg/m(2) every 2 weeks follo

71 was 50 (44-58) years, all were treated with dose-dense doxorubicin, and 48 patients underwent breast

72 She received neoadjuvant dose-dense doxorubicin, cyclophosphamide, and paclitaxel

73 Therefore, we studied dose-dense doxorubicin, paclitaxel, and cyclophosphamide

74 to 65 years of age who completed 4 cycles of dose-dense doxorubicin-cyclophosphamide for stage I-III

75 tim use during the paclitaxel portion of the dose-dense doxorubicin-cyclophosphamide-paclitaxel regim

76 hamide) to (1) enhance treatment efficacy by dose-dense drug delivery and (2) reduce risk of long-ter

77 Efficient induction of early response by dose-dense drug delivery supported an early-response-ada

78 pothesized that 3 months of paclitaxel after dose-dense EC (EC/T) would be superior to CEF or AC/T.

79 rly to detect any difference between CEF and dose-dense EC/T.

80 More cells were killed by PTX dose-dense-equi than with PTX conventional, but with the

81 Dose-dense, every-2-week adjuvant chemotherapy using dox

82 fter 2003, all treatment was administered in dose-dense fashion.

83 17 randomized patients (1006 in the tailored dose-dense group and 1011 in the control group; median [

84 FS events were reported, 118 in the tailored dose-dense group and 151 in the control group (HR, 0.79;

85 s required in six (6%) patients in the Unfav-dose-dense group and 16 (16%) in the Unfav-BEP group.

86 ects occurred in 527 (52.6%) in the tailored dose-dense group and 366 (36.6%) in the control group.

87 ine; 105 were randomly assigned to the Unfav-dose-dense group and 98 to the Unfav-BEP group.

88 cycle of chemotherapy; 1001 in the tailored dose-dense group and 999 in the control group).

89 nd haematotoxic events occurred in the Unfav-dose-dense group compared with in the Unfav-BEP group; t

90 The tailored dose-dense group had significantly better EFS than the c

91 survival was 59% (95% CI 49-68) in the Unfav-dose-dense group versus 48% (38-59) in the Unfav-BEP gro

92 av-BEP group) or a dose-dense regimen (Unfav-dose-dense group), consisting of intravenous paclitaxel

93 c effects were more frequent in the tailored dose-dense group.

94 In the DDP/PTX dose-dense-high scheme, both cell death and regrowth imp

95 Therefore, dose-dense induction and HDT/ASCT are a rational up-fron

96 Dose-dense induction and up-front consolidation with aut

97 Dose-dense induction followed by HDT/ASCT was well toler

98 ch centers and received either six cycles of dose-dense methotrexate, vinblastine, doxorubicin, and c

99 n advanced urothelial cancer, treatment with dose-dense methotrexate, vinblastine, doxorubicin, and c

100 ily, 5 days per week for up to 6.5 weeks) or dose-dense oral temozolomide (75 mg/m(2) once daily for

101 In phase I, treatment was initiated with dose-dense paclitaxel (P) 70 mg/m(2) once daily on days

102 Omission of routine peg-filgrastim during dose-dense paclitaxel according to a prespecified algori

103 atients (90% [95% CI, 83% to 94%]) completed dose-dense paclitaxel within 7 weeks.

104 the safety and feasibility of the sequential dose-dense plan.

105 The results support the option for dose-dense PTX chemotherapy with active single doses, sh

106 to receive either BEP (Unfav-BEP group) or a dose-dense regimen (Unfav-dose-dense group), consisting

107 eated with three BEP (Unfav-BEP) cycles or a dose-dense regimen (Unfav-dose-dense; two cycles of pacl

108 The dose-dense regimen appears promising, with 1-year surviv

109 e first trial that confirms the benefit of a dose-dense regimen over a control regimen containing doc

110 ABVE-PC is a dose-dense regimen that provides outstanding event-free

111 Four-year DFS was 82% for the dose-dense regimens and 75% for the others.

112 Dose-dense regimens should only be used within an approp

113 Dose-dense regimens that require CSFs should only be use

114 ve migrated from a focus on dose-intense and dose-dense regimens, to the use of maintenance therapies

115 s less frequent in patients who received the dose-dense regimens.

116 tine, cyclophosphamide, and doxorubicin with dose-dense rituximab (SC-EPOCH-RR) in newly diagnosed HI

117 e every 3 weeks, with tailored dosing at the dose-dense schedule according to hematologic toxicity.

118 tional and two levels ("equi" and "high") of dose-dense schedules.

119 Dose-dense sequential adjuvant chemotherapy with doxorub

120 evaluation did not predict outcome with this dose-dense, sequential immunochemotherapy program.

121 ve-year DFS was 80% (95% CI, 76% to 85%) for dose-dense therapy and 75% (95% CI, 69% to 80%) for tran

122 d 5-year OS was 88% (95% CI, 84% to 92%) for dose-dense therapy and 84% (95% CI, 79% to 88%) for tran

123 .80 [95% CI, 0.67 to 0.95]); the benefits of dose-dense therapy were seen for ER+ and ER-negative sub

124 determine the safety and feasibility of this dose-dense treatment and to estimate the disease-free an

125 ic therapy with taxanes, platinum agents, or dose-dense treatment can be safely given during pregnanc

126 ompared with standard adjuvant chemotherapy, dose-dense treatment improved breast cancer recurrence-f

127 Dose-dense treatment improved the primary end point, DFS

128 v-BEP) cycles or a dose-dense regimen (Unfav-dose-dense; two cycles of paclitaxel-BEP-oxaliplatin + t

129 to evaluate differences between treatments (dose-dense v standard-dose) on NCB measures from baselin

130 ll, 1,973 patients were randomly assigned to dose-dense versus conventional chemotherapy.

131 phosphamide (EC) administered every 2 weeks (dose-dense) was equivalent to 6 months of CEF.

132 n progression-free and overall survival with dose-dense weekly paclitaxel and 3-weekly (ie, once ever

133 n progression-free and overall survival with dose-dense weekly paclitaxel and 3-weekly carboplatin.

134 We proposed to determine whether dose-dense weekly paclitaxel and carboplatin would prolo

135 aimed to compare efficacy and safety of two dose-dense weekly regimens to standard 3-weekly chemothe

136 A dose-dense weekly schedule of paclitaxel (resulting in a